Omeros Corporation Stock News

Omeros Corporation (NASDAQ:OMER ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman and Chief Executive Off

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended March 31, 2024, on Wednesday, May 15, 2024

Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023, on Monday, April 1, 202

Hidden gems often remain undiscovered within the labyrinth of the stock market. Three stocks with massive upside stand out among the several alternatives as possible titans with significant upside pot

In general, high-growth stocks  and sleeper stocks under $15 are associated with valuation concerns. Let's forget inflated giants and overhyped darlings.

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, of an expanded in

While the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. Rather, it's time to address this speculative p

Omeros Corporation focuses on small-molecule and antibody drugs for common disorders and rare diseases. The company has prioritized the resubmission of its BLA for Narsoplimab for TA-TMA treatment and

Omeros Corporation (NASDAQ:OMER ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive O

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023, on Thursday, November 9, 2023,

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic st

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros' chief medical officer. In his new role, Dr. Grauer will be responsible for